CoChat

Making the Leap from Research Laboratory to Clinic: Challenges and Opportunities for Next-Generation Sequencing in Infectious Disease Diagnostics

Open access

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Next-generation DNA sequencing (NGS) has progressed enormously over the past decade, transforming genomic analysis and opening up many new opportunities for applications in clinical microbiology laboratories. The impact of NGS on microbiology has been revolutionary, with new microbial genomic sequences being generated daily, leading to the development of large databases of genomes and gene sequences. The ability to analyze microbial communities without culturing organisms has created the ever-growing field of metagenomics and microbiome analysis and has generated significant new insights into the relation between host and microbe. The medical literature contains many examples of how this new technology can be used for infectious disease diagnostics and pathogen analysis. The implementation of NGS in medical practice has been a slow process due to various challenges such as clinical trials, lack of applicable regulatory guidelines, and the adaptation of the technology to the clinical environment. In April 2015, the American Academy of Microbiology (AAM) convened a colloquium to begin to define these issues, and in this document, we present some of the concepts that were generated from these discussions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/mbio.01888-15

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG 1 NGS genome analysis. The general process of using NGS for analysis of a single genome is depicted in this figure. Note that there are many variations on this approach. Purified DNA (i.e., input genome) is fragmented and run through the DNA sequencing process. The sequencing instrument produces either short (e.g., for Illumina) or long (e.g., for Pacific Biosciences) sequence reads depending on the platform used. When the goal is to produce a complete genome (e.g., for identifying virulence or antibiotic resistance genes or for comparative genomic studies), the reads are assembled into genomes using specialized software. Some gaps in the assembly may occur, leading to a draft genome sequence composed of many contigs. When the genome is assembled without gaps, it is said to be closed. When the goal is to identify variants (e.g., SNPs) with respect to a reference genome, the reads can be aligned directly with the reference genome and sequence variants can be identified using specialized programs. These variants serve to define the organism at the subspecies and strain level and are useful in epidemiological tracking as well as to identify mutations that occur.
FIG 1 NGS genome analysis. The general process of using NGS for analysis of a single genome is depicted in this figure. Note that there are many variations on this approach. Purified DNA (i.e., input genome) is fragmented and run through the DNA sequencing process. The sequencing instrument produces either short (e.g., for Illumina) or long (e.g., for Pacific Biosciences) sequence reads depending on the platform used. When the goal is to produce a complete genome (e.g., for identifying virulence or antibiotic resistance genes or for comparative genomic studies), the reads are assembled into genomes using specialized software. Some gaps in the assembly may occur, leading to a draft genome sequence composed of many contigs. When the genome is assembled without gaps, it is said to be closed. When the goal is to identify variants (e.g., SNPs) with respect to a reference genome, the reads can be aligned directly with the reference genome and sequence variants can be identified using specialized programs. These variants serve to define the organism at the subspecies and strain level and are useful in epidemiological tracking as well as to identify mutations that occur.CC BY-NC-SA · PubMed Central
FIG 2 NGS workflow. A high-level overview of the steps taken in the NGS data production process and some of the equipment and software used in this process. The specific instruments and programs may vary as there are multiple solutions (e.g., Table 2). DB, database; QA, quality assurance; seq’ing, sequencing; conc, concentration; LIMS, laboratory information management system.
FIG 2 NGS workflow. A high-level overview of the steps taken in the NGS data production process and some of the equipment and software used in this process. The specific instruments and programs may vary as there are multiple solutions (e.g., Table 2). DB, database; QA, quality assurance; seq’ing, sequencing; conc, concentration; LIMS, laboratory information management system.CC BY-NC-SA · PubMed Central
FIG 3 Potential clinical applications for metagenomics sequencing. There are numerous potential applications of NGS technology to the clinical microbiology laboratory. Each entry in the chart represents a potential area for the utilization of NGS diagnostics and/or future research.
FIG 3 Potential clinical applications for metagenomics sequencing. There are numerous potential applications of NGS technology to the clinical microbiology laboratory. Each entry in the chart represents a potential area for the utilization of NGS diagnostics and/or future research.CC BY-NC-SA · PubMed Central
FIG 4 The FDA is considering the following information for the clearance/approval of an infectious disease NGS-based test/assay. The FDA presubmission process can be utilized for outstanding questions and to request additional information while policy is still being developed (26). IRB, institutional review board.
FIG 4 The FDA is considering the following information for the clearance/approval of an infectious disease NGS-based test/assay. The FDA presubmission process can be utilized for outstanding questions and to request additional information while policy is still being developed (26). IRB, institutional review board.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Research works printed but not linked: 4

  1. GenomeWeb 7 8 2015 CDC earmarks $2.3 million for NGS, bioinformatic approaches to combat infectious disease. GenomeWeb, New York, NY https://www.genomeweb.com/research-funding/cdc-earmarks-23m-ngs-bioinformatic-approaches-combat-infectious-disease.
  2. US Food and Drug Administration 11 7 2014 Public workshop—advancing regulatory science for high throughput sequencing devices for microbial identification and detection of antimicrobial resistance markers, April 1, 2014. US Food and Drug Administration, Silver Spring, MD http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm386967.htm.
  3. US Food and Drug Administration 11 12 2013 FDA database for regulatory grade microbial sequences (FDA-ARGOS): supporting development and validation of infectious disease Dx tests. National Center for Biotechnology Information, Bethesda, MD http://www.ncbi.nlm.nih.gov/bioproject/231221.
  4. Sichtig H 2014 High-throughput sequencing technologies for microbial identification and detection of antimicrobial resistance markers, p 1– 21. In FDA Public Workshop on High Throughput Sequencing Devices in Microbial Diagnostics. US Food and Drug Administration, Silver Spring, MD.

Cited by

See all 382

Metadata

Authors
Goldberg, B., Sichtig, H., Geyer, C., Ledeboer, N., & Weinstock, G. M.
Affiliations
  • Children's National (US)
  • United States Food and Drug Administration (US)
  • American Society for Microbiology (US)
  • Medical College of Wisconsin (US)
  • The Jackson Laboratory for Genomic Medicine (US)
Corresponding author
Weinstock, George M.
Venue
mBio
Published
2015-12-31
Volume
6
Issue
6
Pages
e01888-15
ISSN
  • 2150-7511 (ISSN-L)
  • 2161-2129
OpenAlex
W2239037555
Cited by
360
References
30
Citations by year
2026: 19 · 2025: 38 · 2024: 38 · 2023: 47 · 2022: 56 · 2021: 42 · 2020: 34 · 2019: 27 · 2018: 17 · 2017: 26 · 2016: 16
FWCI
1.95
Type
journal article
Language
en
Open access
Licence
Locations
  • mBio (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
Topics
  • Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Phylogenetic Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords
next-generation sequencing, infectious disease diagnostics, clinical microbiology, metagenomics, microbiome analysis, pathogen genomics, clinical implementation, regulatory guidelines, clinical trials, host-microbe interactions
MeSH terms
Communicable Diseases, Microbiological Techniques, Societies, Scientific, United States, Molecular Diagnostic Techniques, High-Throughput Nucleotide Sequencing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Making the Leap from Research Laboratory to Clinic: Challenges and Opportunities for Next-Generation Sequencing in Infectious Disease Diagnostics. https://app.cochat.ai/papers/10.1128/mbio.01888-15
The paper
Goldberg, B., Sichtig, H., Geyer, C., Ledeboer, N., & Weinstock, G. M. (2015). Making the Leap from Research Laboratory to Clinic: Challenges and Opportunities for Next-Generation Sequencing in Infectious Disease Diagnostics. mBio. https://doi.org/10.1128/mbio.01888-15

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.